Perspective Therapeutics, Inc. (CATX) Price Prediction & ForecastCATXPerspective Therapeutics, Inc.

Alphio's CATX stock price prediction model matches the current Perspective Therapeutics, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.60 (-0.82%). The 1-week path is $1.63 (+1.42%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Currently, CATX is not a good buy due to its significant price decline of 25.81% over the past five days and a very low RSI of 15.772, indicating it is oversold. The forward P/E ratio is 25.7069, suggesting that the stock is expensive relative to its earnings potential. Additionally, the stock has a price-to-sales ratio of 630.76, which is extremely high, indicating overvaluation. The main risk is the negative sentiment reflected in the recent downgrades from analysts, with Piper Sandler lowering its price target to $14, which is still significantly above the current price of $1.61. Therefore, it is advisable to avoid purchasing CATX at this time.

Perspective Therapeutics, Inc. (CATX) last closed at $1.61, losing -28.76%. These facts feed the 1-day and 1-week CATX price prediction above.